List of Veklury drug patents
Veklury is owned by Gilead Sciences Inc.
Veklury contains Remdesivir.
Veklury has a total of 13 drug patents out of which 0 drug patents have expired.
Veklury was authorised for market use on 22 October, 2020.
Veklury is available in powder;intravenous, solution;intravenous dosage forms.
Veklury can be used as treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg), treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog or sale thereof, is not recommended; treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt thereof, is not recommended, treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization, treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization; treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg).
Drug patent challenges can be filed against Veklury from October, 2024.
The generics of Veklury are possible to be released after 28 May, 2041.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8318682 | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(6 years from now) | |
| USRE46762 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(6 years from now) | |
| US8008264 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Sep, 2029
(6 years from now) | |
| US10065958 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Sep, 2031
(8 years from now) | |
| US11492353 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Dec, 2031
(8 years from now) | |
| US9949994 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(12 years from now) | |
| US9724360 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10695361 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
| US11007208 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
| US11382926 | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
| US10675296 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(15 years from now) | |
| US11266681 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(15 years from now) | |
| US11491169 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 22, 2025 |
| New Patient Population (NPP) | Apr 25, 2025 |
| New Dosing Schedule (D) | Jan 21, 2025 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: October, 2024
Market Authorisation Date: 22 October, 2020
Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization and for whom concomitant use of chloroquine, or an analog or sale thereof, is not recommended; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt thereof, is not recommended
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic